Inhibrx (INBX) Short Interest Ratio & Short Volume $12.22 -0.11 (-0.92%) Closing price 03:58 PM EasternExtended Trading$12.28 +0.06 (+0.47%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Inhibrx Short Interest DataInhibrx (INBX) has a short interest of 757,300 shares, representing 7.54% of the float (the number of shares available for trading by the public). This marks a -18.94% decrease in short interest from the previous month. The short interest ratio (days to cover) is 7.0, indicating that it would take 7.0 days of the average trading volume of 196,528 shares to cover all short positions.Current Short Interest757,300 sharesPrevious Short Interest934,200 sharesChange Vs. Previous Month-18.94%Dollar Volume Sold Short$8.93 millionShort Interest Ratio7.0 Days to CoverLast Record DateApril 15, 2025Outstanding Shares14,476,000 sharesFloat Size10,040,000 sharesShort Percent of Float7.54%Today's Trading Volume69,569 sharesAverage Trading Volume196,528 sharesToday's Volume Vs. Average35% Short Selling Inhibrx? Sign up to receive the latest short interest report for Inhibrx and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINBX Short Interest Over TimeINBX Days to Cover Over TimeINBX Percentage of Float Shorted Over Time Inhibrx Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2025757,300 shares $8.93 million -18.9%7.5%7 $11.79 3/31/2025934,200 shares $13.07 million -2.2%9.3%8.6 $13.99 3/15/2025955,400 shares $13.47 million -19.7%9.6%10.5 $14.10 2/28/20251,190,000 shares $15.77 million -7.0%12.0%13.6 $13.25 2/15/20251,280,000 shares $17.14 million +4.9%13.0%15.6 $13.39 1/31/20251,220,000 shares $16.57 million -5.4%12.3%14.1 $13.58 1/15/20251,290,000 shares $17.38 million +3.2%13.0%17 $13.47 12/31/20241,250,000 shares $19.25 million +4.2%12.6%17.4 $15.40 12/15/20241,200,000 shares $17.54 million +10.1%12.1%15.5 $14.62 11/30/20241,090,000 shares $16.63 million +5.8%11.0%12.9 $15.26 Get the Latest News and Ratings for INBX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. 11/15/20241,030,000 shares $14.24 million +5.5%10.3%11.2 $13.83 10/31/2024976,700 shares $15.66 million +9.0%9.7%10.9 $16.03 10/15/2024895,700 shares $14.10 million +20.6%8.9%9.2 $15.74 9/30/2024742,500 shares $11.63 million +9.6%7.4%6.9 $15.66 9/15/2024677,700 shares $11.12 million -3.3%6.7%5.2 $16.41 8/31/2024700,700 shares $10.20 million -6.9%6.9%4.5 $14.56 8/15/2024752,900 shares $9.33 million +6.0%7.3%3.7 $12.40 7/31/2024710,400 shares $10.31 million -3.0%7.0%3.1 $14.51 7/15/2024732,600 shares $10.15 million No Change7.2%2.7 $13.86 5/15/20242,050,000 shares $70.46 million -6.4%N/A3.8 $34.37 4/30/20242,190,000 shares $74.55 million -0.5%N/A4.7 $34.04 4/15/20242,200,000 shares $76.43 million +2.3%6.2%3.2 $34.74 3/31/20242,150,000 shares $75.16 million +34.4%6.0%3 $34.96 3/15/20241,600,000 shares $56 million -18.0%4.5%2.1 $35.00 2/29/20241,950,000 shares $71.43 million -7.1%5.5%2.6 $36.63 2/15/20242,100,000 shares $79.78 million -12.5%5.9%3 $37.99 1/31/20242,400,000 shares $92.47 million -41.3%6.7%3.4 $38.53 1/15/20244,090,000 shares $142.74 million +20.3%11.5%6.1 $34.90 12/31/20233,400,000 shares $129.20 million -6.1%9.6%7.4 $38.00 12/15/20233,620,000 shares $101.83 million -30.1%10.2%8.9 $28.13 11/30/20235,180,000 shares $107.59 million -2.1%15.0%12 $20.77 11/15/20235,290,000 shares $107.23 million +5.4%15.3%12 $20.27 10/31/20235,020,000 shares $77.66 million +1.0%15.0%11.2 $15.47 10/15/20234,970,000 shares $87.97 million -7.1%14.9%10.5 $17.70 9/30/20235,350,000 shares $98.17 million +11.2%16.0%11.9 $18.35 9/15/20234,810,000 shares $100.58 million -5.5%14.4%11.3 $20.91 8/31/20235,090,000 shares $108.93 million -12.8%15.3%12.8 $21.40 8/15/20235,840,000 shares $99.69 million +1.7%17.5%15.7 $17.07 7/31/20235,740,000 shares $115.09 million +0.9%18.0%16.4 $20.05 7/15/20235,690,000 shares $138.32 million -1.4%17.9%17 $24.31The collapse has already started (Ad)The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.Watch the 2025 Trade War dividend protection briefing now 6/30/20235,770,000 shares $149.79 million -4.0%18.2%16 $25.96 6/15/20236,010,000 shares $167.20 million +1.0%20.4%15.8 $27.82 5/31/20235,950,000 shares $140.78 million +3.3%20.2%15.4 $23.66 5/15/20235,760,000 shares $144.86 million +0.4%19.6%13.8 $25.15 4/30/20235,740,000 shares $120.54 million -2.1%19.5%14.1 $21.00 4/15/20235,860,000 shares $106.95 million -0.3%19.9%15.1 $18.25 3/31/20235,880,000 shares $110.96 million -3.0%20.0%14.5 $18.87 3/15/20236,060,000 shares $136.71 million +7.8%20.6%14.4 $22.56 2/28/20235,620,000 shares $135.22 million +8.5%19.1%12.9 $24.06 2/15/20235,180,000 shares $120.90 million -1.7%17.6%12.3 $23.34 1/31/20235,270,000 shares $131.75 million -3.0%19.1%11.7 $25.00 1/15/20235,430,000 shares $128.47 million +26.3%18.1%11.3 $23.66 12/30/20224,300,000 shares $105.95 million +8.6%14.4%8.5 $24.64 12/15/20223,960,000 shares $110.96 million -10.8%13.2%5.4 $28.02 11/30/20224,440,000 shares $133.11 million -1.1%15.7%5.7 $29.98 11/15/20224,490,000 shares $146.82 million -2.8%15.9%5.8 $32.70 10/31/20224,620,000 shares $148.67 million +16.7%18.0%6.2 $32.18 10/15/20223,960,000 shares $118.21 million -4.1%15.5%5.5 $29.85 9/30/20224,130,000 shares $74.13 million +25.5%16.2%5.9 $17.95 9/15/20223,290,000 shares $48.66 million +0.6%12.9%6.9 $14.79 8/31/20223,270,000 shares $58.01 million +0.3%12.8%7.2 $17.74 8/15/20223,260,000 shares $80.46 million -13.3%12.8%7.5 $24.68 7/31/20223,760,000 shares $65.20 million +5.3%14.4%7.7 $17.34 7/15/20223,570,000 shares $61.69 million +15.2%13.7%7.2 $17.28 6/30/20223,100,000 shares $35.19 million -9.6%11.9%6.5 $11.35 6/15/20223,430,000 shares $30.73 million +4.6%13.2%8 $8.96 5/31/20223,280,000 shares $42.87 million +35.0%12.6%8.8 $13.07 5/15/20222,430,000 shares $41.16 million +12.0%9.4%7.2 $16.94 4/30/20222,170,000 shares $34.39 million +7.4%8.3%7.6 $15.85 4/15/20222,020,000 shares $37.01 million -10.2%7.7%7.1 $18.32 3/31/20222,250,000 shares $50.13 million +8.7%8.6%8 $22.28 3/15/20222,070,000 shares $41.77 million +0.5%7.9%7.4 $20.18 2/28/20222,060,000 shares $44.29 million -3.3%7.9%7 $21.50 2/15/20222,130,000 shares $51.87 million +13.3%8.2%7.5 $24.35 1/31/20221,880,000 shares $49.93 million +67.9%8.3%7.3 $26.56 1/15/20221,120,000 shares $35.26 million +4.7%N/A0 $31.48 12/31/20211,070,000 shares $46.73 million +56.0%4.7%4.5 $43.67 12/15/2021685,900 shares $27.83 million +5.6%3.0%2.9 $40.58 11/30/2021649,700 shares $26.27 million +1.3%2.9%3.3 $40.43 11/15/2021641,400 shares $28.54 million -25.2%2.8%3.4 $44.49 10/29/2021857,700 shares $34.47 million +4.1%3.8%4.6 $40.19 10/15/2021823,900 shares $32.72 million -3.8%3.7%4.7 $39.71 9/30/2021856,500 shares $28.53 million +17.6%3.8%6.5 $33.31 9/15/2021728,400 shares $26.37 million -10.0%3.2%4 $36.20 8/31/2021808,900 shares $23.07 million -20.7%3.6%4 $28.52 8/13/20211,020,000 shares $28.18 million -8.1%4.5%4.5 $27.63 7/30/20211,110,000 shares $31.59 million +0.9%4.9%5.1 $28.46 7/15/20211,100,000 shares $27.70 million -1.8%4.9%5.3 $25.18 6/30/20211,120,000 shares $30.82 million +35.0%5.0%5.3 $27.52 6/15/2021829,900 shares $21.54 million +6.5%3.7%5.2 $25.95The collapse has already started (Ad)The headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.Watch the 2025 Trade War dividend protection briefing now 5/28/2021779,100 shares $16.49 million +1.3%3.5%6.4 $21.16 5/14/2021768,900 shares $12.93 million -8.2%3.4%6.6 $16.82 4/30/2021837,100 shares $16.43 million +5.1%3.7%5.3 $19.63 4/15/2021796,400 shares $16.58 million +52.1%3.6%5.3 $20.82 3/31/2021523,600 shares $8.86 million -21.7%2.3%3.6 $16.93 3/15/2021668,400 shares $15.71 million +19.6%3.0%3.9 $23.51 2/26/2021558,800 shares $14.98 million -8.2%2.5%3.3 $26.80 2/12/2021608,900 shares $22.53 million +4.3%2.7%3.9 $37.00 1/29/2021583,800 shares $19.08 million -16.8%2.6%5.7 $32.68 1/15/2021701,600 shares $25.26 million No Change3.2%6.6 $36.00 INBX Short Interest - Frequently Asked Questions What is Inhibrx's current short interest? Short interest is the volume of Inhibrx shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 757,300 shares of INBX short. 7.54% of Inhibrx's shares are currently sold short. Learn More on Inhibrx's current short interest. What is a good short interest ratio for Inhibrx? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INBX shares currently have a short interest ratio of 7.0. Learn More on Inhibrx's short interest ratio. Which institutional investors are shorting Inhibrx? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Inhibrx: CSS LLC IL, Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Inhibrx? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.54% of Inhibrx's floating shares are currently sold short. Is Inhibrx's short interest increasing or decreasing? Inhibrx saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 757,300 shares, a decrease of 18.9% from the previous total of 934,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Inhibrx's float size? Inhibrx currently has issued a total of 14,476,000 shares. Some of Inhibrx's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Inhibrx currently has a public float of 10,040,000 shares. How does Inhibrx's short interest compare to its competitors? 7.54% of Inhibrx's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Inhibrx: Dianthus Therapeutics, Inc. (26.50%), AnaptysBio, Inc. (53.39%), Xeris Biopharma Holdings, Inc. (13.39%), Arbutus Biopharma Co. (6.07%), ChromaDex Co. (4.29%), Arvinas, Inc. (11.86%), KalVista Pharmaceuticals, Inc. (14.04%), Trevi Therapeutics, Inc. (10.17%), Keros Therapeutics, Inc. (14.12%), Pharming Group (0.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Inhibrx stock? Short selling INBX is an investing strategy that aims to generate trading profit from Inhibrx as its price is falling. INBX shares are trading down $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Inhibrx? A short squeeze for Inhibrx occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INBX, which in turn drives the price of the stock up even further. How often is Inhibrx's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INBX, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies DNTH Short Squeeze ANAB Short Squeeze XERS Short Squeeze ABUS Short Squeeze CDXC Short Squeeze ARVN Short Squeeze KALV Short Squeeze TRVI Short Squeeze KROS Short Squeeze PHAR Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INBX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.